Ray Barlow is the founder of SynOx Therapeutics. SynOx Therapeutics has raised $92M in total funding. Latest round: Series B. Based in Dublin, Ireland.
Ray Barlow is the CEO of SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT). The company has secured significant funding, including a €37M Series A and a $92M Series B, to advance emactuzumab through clinical trials. Barlow brings over 20 years of experience in the biopharmaceutical industry, having held leadership roles in scientific, clinical, commercial, and executive capacities at various global pharmaceutical and biotech companies.
Full founder directory · Investor directory · Company funding database · Fundraising library